Skip to content
Stack & save: 10% off 3+ vials, 15% off 5+ · Free shipping over $250
Cart 0
Compound Files

FOXO4 Research Guide: The Protein, the DRI Peptide, and the Evidence

FOXO4 is a protein name, while FOXO4-DRI identifies a particular research peptide. This distinction is essential when interpreting senescent-cell experiments or matching a sample to a study.

Hero Peptides Research TeamUpdated Nov 20265 min read

Quick facts

Catalog name FOXO4
Hero catalog size 10 mg
Naming distinction FOXO4 protein and FOXO4-DRI research peptide are different materials
Research themes Transcription-factor biology, p53 interactions, and cellular senescence
Product identity Exact sequence and DRI designation are unconfirmed in the supplied export
Hero product FOXO4

FOXO4 and FOXO4-DRI are related research terms, but they do not name the same material. FOXO4 is a transcription factor. FOXO4-DRI is a designed peptide studied in work on the FOXO4–p53 interaction and the survival of senescent cells.

Hero’s supplied catalog lists FOXO4 in a 10 mg format without identifying its sequence or confirming a DRI designation. This guide explains the literature distinction. It does not assume that the catalog material is the peptide used in a particular paper.

What FOXO4 means: a protein name is not a peptide specification

Research on FOXO4 includes its activity as a transcription factor and its involvement in cell-state regulation. De Keizer and colleagues investigated FOXO-related responses in an oncogenic BRAF model, connecting the tested signaling context with p21-dependent senescence (de Keizer et al., 2010).

That work concerns a biological protein and pathway. It is different from introducing a peptide designed to interfere with a protein interaction. The distinction should remain visible even when a search result shortens both subjects to FOXO4.

A laboratory sample could be a protein, a fragment, or a modified peptide, and those possibilities require different descriptions. The catalog name alone cannot settle which one is present. Match the actual sequence, stereochemistry, modifications, and chemical form before connecting a sample with published results.

How FOXO4-DRI research approaches senescent cells

Baar and colleagues reported targeted apoptosis of senescent cells using FOXO4-DRI in 2017. Their experiments examined the FOXO4–p53 interaction, senescent-cell responses, and outcomes in mouse models. The designed peptide was a specific test article, not simply the full FOXO4 protein (Baar et al., 2017).

The DRI designation refers to a D-retro-inverso design. Sequence orientation and stereochemistry therefore belong in the identity check. A superficially similar amino-acid list without those details does not establish that two preparations are equivalent.

The mechanistic hypothesis also needs a defined endpoint. Demonstrating interaction with p53, measuring cell viability, and measuring an organism-level response are different experiments. Evidence at one step can motivate another without establishing the entire proposed sequence of effects.

What the FOXO4 studies actually measured

The research record includes pathway experiments, a designed senolytic peptide, and structural work on molecular interactions. These contributions answer different questions.

Study Research setting Contribution Boundary
de Keizer et al., 2010 Oncogenic BRAF and FOXO-related cell work Examined p21-dependent senescence Not an experiment on a generic FOXO4-labeled vial
Baar et al., 2017 FOXO4-DRI cell and mouse experiments Investigated targeted senescent-cell apoptosis Findings belong to the designed peptide and tested models
Bourgeois et al., 2025 Molecular and structural interaction studies Characterized interactions involving p53’s transactivation domain Binding information is not a human longevity outcome

Bourgeois and colleagues examined the interaction of p53 with FOXO4 and FOXO4-DRI, including structural characterization of complexes involving the p53 transactivation domain. This helps refine the molecular question rather than treating a protein interaction as an unexplained black box (Bourgeois et al., 2025).

None of these papers identifies Hero’s supplied material. Scientific background and product identification are separate tasks, and both are necessary before claiming that a catalog sample reproduces a published test article.

What a senolytic finding does not establish

A lower viability measurement is not automatically evidence of selective senescent-cell removal. A meaningful selectivity claim needs an appropriate comparison with other cells and conditions. Otherwise, the result may show cell loss without establishing why that loss occurred.

Likewise, senescence is not a complete synonym for aging. A cell-state experiment cannot by itself establish that an intervention reverses human aging, extends lifespan, or improves every tissue. The cited preclinical work should retain its actual models and endpoints.

Other aging-related topics, such as the Epithalon telomere literature, involve different molecules and mechanisms. Sharing a place in a longevity discussion does not make their findings interchangeable or establish that the materials should be combined.

Laboratory planning starts with identity

For the 10 mg catalog entry, confirm whether the label and matching documentation identify FOXO4-DRI or another material. A nominal quantity does not supply sequence, folding state, stereochemical design, or a final solution concentration.

If investigating a defined DRI peptide, use documentation and analytical methods capable of supporting that identity. If investigating a protein, the relevant structural and functional requirements will differ. Start with the material rather than choosing a preparation method from an ambiguous abbreviation.

Document whether the comparison measures cell survival, a senescence marker, or direct molecular interaction; each supports a different conclusion.

For cell-based studies, define the senescence model, comparator populations, viability measurements, and any additional markers needed for the question. No single favorable-looking signal establishes every part of a proposed senolytic mechanism.

Use validated preparation and documented storage conditions. Retain lot and handling records with the experiment. Chemical identification and a suitable biological comparison make the evidence more informative than a broad claim based only on the catalog name.

FOXO4 research FAQ

Is FOXO4 the same as FOXO4-DRI?

No. FOXO4 names a protein; FOXO4-DRI names a designed peptide. Related terminology does not make them the same test article.

Does Hero’s export confirm the DRI form?

No. It lists FOXO4 and 10 mg but does not provide the sequence or DRI designation. Those details remain to be confirmed.

Do the cited studies establish human age reversal?

No. The cited molecular, cellular, and mouse studies do not establish that clinical outcome.

What should be matched before using a paper’s method?

Match the exact material, sequence design, chemical form, model, and endpoint. A shared FOXO4 label is insufficient to establish equivalence.

FOXO4. View catalog product

References

  1. de Keizer PLJ, et al. Activation of forkhead box O transcription factors by oncogenic BRAF promotes p21cip1-dependent senescence. Cancer Res. 2010;70:8526-8536. Source.
  2. Baar MP, et al. Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. Cell 2017;169:132-147.e16. Source.
  3. Bourgeois B, et al. The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI. Nat Commun. 2025;16:5672. Source.
For laboratory research use only. Not for human or veterinary use. This article is educational and is not medical advice.

Read next

Add 3 vials for 10% off
Build my stack